Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Greil, Richard"" wg kryterium: Autor


Wyświetlanie 1-19 z 19
Tytuł:
Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort
Autorzy:
Schlintl, Verena
Huemer, Florian
Rinnerthaler, Gabriel
Melchardt, Thomas
Winder, Thomas
Reimann, Patrick
Riedl, Jakob
Amann, Arno
Eisterer, Wolfgang
Romeder, Franz
Piringer, Gudrun
Ilhan-Mutlu, Aysegül
Wöll, Ewald
Greil, Richard
Weiss, LukasAff1, IDs12885021091156_cor15
Pokaż więcej
Źródło:
BMC Cancer. 22(1)
Czasopismo naukowe
Tytuł:
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
Autorzy:
Gampenrieder, Simon PeterAff1, Aff2, Aff3
Rinnerthaler, GabrielAff1, Aff2, Aff3
Tinchon, Christoph
Petzer, Andreas
Balic, Marija
Heibl, Sonja
Schmitt, Clemens
Zabernigg, August Felix
Egle, Daniel
Sandholzer, Margit
Singer, Christian Fridolin
Roitner, Florian
Hager, Christopher
Andel, Johannes
Hubalek, Michael
Knauer, Michael
Greil, RichardAff1, Aff2, Aff3, IDs1305802101492x_cor17
Pokaż więcej
Źródło:
Breast Cancer Research. 23(1)
Czasopismo naukowe
Tytuł:
Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR)
Autorzy:
Gampenrieder, Simon PeterAff1, Aff2
Peer, Andreas
Weismann, Christian
Meissnitzer, Matthias
Rinnerthaler, GabrielAff1, Aff2
Webhofer, Johanna
Westphal, Theresa
Riedmann, Marina
Meissnitzer, Thomas
Egger, Heike
Klaassen Federspiel, Frederike
Reitsamer, Roland
Hauser-Kronberger, Cornelia
Stering, Katharina
Hergan, Klaus
Mlineritsch, Brigitte
Greil, RichardAff1, Aff2
Pokaż więcej
Źródło:
Breast Cancer Research. 21(1)
Czasopismo naukowe
Tytuł:
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
Autorzy:
Rinnerthaler, Gabriel
Gampenrieder, Simon Peter
Petzer, Andreas
Burgstaller, Sonja
Fuchs, David
Rossmann, Dieter
Balic, Marija
Egle, Daniel
Rumpold, Holger
Singer, Christian F.
Bartsch, Rupert
Petru, Edgar
Melchardt, Thomas
Ulmer, Hanno
Mlineritsch, Brigitte
Greil, Richard
Pokaż więcej
Temat:
BREAST cancer patients
TRIPLE-negative breast cancer
ANTINEOPLASTIC agents
PROTEASOME inhibitors
MULTIPLE myeloma
Źródło:
BMC Cancer; 11/6/2018, Vol. 18 Issue 1, p1-9, 9p, 1 Diagram, 2 Charts
Czasopismo naukowe
Tytuł:
Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Autorzy:
Huemer, Florian
Thaler, Josef
Piringer, Gudrun
Hackl, Hubert
Pleyer, Lisa
Hufnagl, Clemens
Weiss, Lukas
Greil, Richard
Pokaż więcej
Temat:
GENETICS of colon cancer
GENETIC mutation
EPIDERMAL growth factor receptors
ENDOTHELIAL growth factors
COLON cancer patients
Źródło:
BMC Cancer; 1/3/2018, Vol. 18, p1-N.PAG, 11p, 1 Diagram, 3 Charts, 5 Graphs
Czasopismo naukowe
Tytuł:
The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.
Autorzy:
Wolff, Florian
Leisch, Michael
Greil, Richard
Risch, Angela
Pleyer, Lisa
Pokaż więcej
Temat:
DNA methylation
TUMOR microenvironment
ENDOGENOUS retroviruses
DECITABINE
AZACITIDINE
ACUTE myeloid leukemia
Źródło:
Cell Communication & Signaling; 3/31/2017, Vol. 15, p1-14, 14p
Czasopismo naukowe
Tytuł:
T cells in multiple myeloma display features of exhaustion and senescence at the tumor site.
Autorzy:
Zelle-Rieser, Claudia
Thangavadivel, Shanmugapriya
Biedermann, Rainer
Brunner, Andrea
Stoitzner, Patrizia
Willenbacher, Ella
Greil, Richard
Jöhrer, Karin
Pokaż więcej
Temat:
T cells
MULTIPLE myeloma
BONE marrow
IMMUNOTHERAPY
CYTOKINES
Źródło:
Journal of Hematology & Oncology; 11/3/2016, Vol. 9, p1-12, 12p
Czasopismo naukowe
Tytuł:
Cytomegalovirus reactivation and its clinical impact in patients with solid tumors.
Autorzy:
Schlick, Konstantin
Grundbichler, Michael
Auberger, Jutta
Kern, Jan Marco
Hell, Markus
Hohla, Florian
Hopfinger, Georg
Greil, Richard
Pokaż więcej
Temat:
TUMOR classification
CYTOMEGALOVIRUS diseases
EPSTEIN-Barr virus
POLYMERASE chain reaction
RETROSPECTIVE studies
Źródło:
Infectious Agents & Cancer; 12/3/2015, Vol. 10, p1-4, 4p, 1 Chart
Czasopismo naukowe
Tytuł:
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study.
Autorzy:
Thaler, Josef
Karthaus, Meinolf
Mineur, Laurent
Greil, Richard
Letocha, Henry
Hofheinz, Ralf
Fernebro, Eva
Gamelin, Erick
Ba¤os, Ana
K”hne, Claus-Henning
Pokaż więcej
Temat:
COLON cancer
EPIDERMAL growth factor receptors
CANCER chemotherapy
QUALITY of life
KAPLAN-Meier estimator
TOXICITY testing
Źródło:
BMC Cancer; 2012, Vol. 12 Issue 1, p438-447, 10p, 1 Chart, 7 Graphs
Czasopismo naukowe
Tytuł:
Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group.
Autorzy:
Reinacher-Schick, Anke
Schulmann, Karsten
Modest, Dominik P
Bruns, Nina
Graeven, Ulrich
Jaworska, Malgorzata
Greil, Richard
Porschen, Rainer
Arnold, Dirk
Schmiegel, Wolff
Tannapfel, Andrea
Pokaż więcej
Temat:
COLON cancer patients
GENETIC code
OXALIPLATIN
DRUG therapy
GENETIC mutation
Źródło:
BMC Cancer; 2012, Vol. 12 Issue 1, p349-356, 8p, 1 Diagram, 5 Charts, 1 Graph
Czasopismo naukowe
Tytuł:
CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.
Autorzy:
Melchardt, Thomas
Hufnagl, Clemens
Magnes, Teresa
Weiss, Lukas
Hutarew, Georg
Neureiter, Daniel
Schlattau, Alexander
Moser, Gerhard
Gaggl, Alexander
Tränkenschuh, Wolfgang
Greil, Richard
Egle, Alexander
Pokaż więcej
Temat:
CISPLATIN
FLUOROURACIL
GENETIC polymorphisms
HEAD tumors
HYDROCARBONS
NECK tumors
OXIDOREDUCTASES
PROGNOSIS
GENOTYPES
Źródło:
BMC Cancer; 2015, Vol. 15 Issue 1, p725-725, 1p
Czasopismo naukowe
Tytuł:
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial.
Autorzy:
Schimanski, Carl Christoph
Möhler, Markus
Schön, Michael
van Cutsem, Eric
Greil, Richard
Bechstein, Wolf Otto
Hegewisch-Becker, Susanna
von Wichert, Götz
Vöhringer, Matthias
Heike, Michael
Heinemann, Volker
Peeters, Marc
Kanzler, Stephan
Kasper, Stefan
Overkamp, Friedrich
Schröder, Jan
Seehofer, Daniel
Kullmann, Frank
Linz, Bernhard
Schmidtmann, Irene
Pokaż więcej
Źródło:
BMC Cancer; 2012, Vol. 12 Issue 1, p144-144, 1p
Czasopismo naukowe
Tytuł:
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
Autorzy:
Pleyer L; 3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria. .; Center for Clinical Cancer and Immunology Trials at Salzburg Cancer Research Institute, Salzburg, Austria. .; Cancer Cluster Salzburg, Salzburg, Austria. .
Burgstaller S; Department of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria.
Stauder R; Department of Internal Medicine V, Innsbruck Medical University, Innsbruck, Austria.
Girschikofsky M; Department of Hematology and Oncology, Elisabethinen Hospital, Linz, Austria.
Sill H; Department of Hematology, Medical University of Graz, Graz, Austria.
Schlick K; 3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria.; Center for Clinical Cancer and Immunology Trials at Salzburg Cancer Research Institute, Salzburg, Austria.; Cancer Cluster Salzburg, Salzburg, Austria.
Thaler J; Department of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria.
Halter B; Department of Internal Medicine V, Innsbruck Medical University, Innsbruck, Austria.
Machherndl-Spandl S; Department of Hematology and Oncology, Elisabethinen Hospital, Linz, Austria.
Zebisch A; Department of Hematology, Medical University of Graz, Graz, Austria.
Pichler A; Department for Hematology and Oncology, LKH Leoben, Leoben, Austria.
Pfeilstöcker M; 3rd Medical Department for Hematology and Oncology, Hanusch Hospital, Vienna, Austria.
Autzinger EM; First Medical Department, Center for Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna, Austria.
Lang A; Department of Internal Medicine, LKH Feldkirch, Feldkirch, Austria.
Geissler K; 5th Medical Department, Hospital Hietzing, Vienna, Austria.
Voskova D; Department of Internal Medicine III, General Hospital, Linz, Austria.
Geissler D; 1st Medical department, Klinikum Klagenfurt, Klagenfurt, Austria.
Sperr WR; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Hojas S; Department of Internal Medicine, LKH Fürstenfeld, Fürstenfeld, Austria.
Rogulj IM; Department of Hematology, Clinical Hospital Merkur, Zagreb, Croatia.
Andel J; Department of Internal Medicine II, LKH Steyr, Steyr, Austria.
Greil R; 3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria.; Center for Clinical Cancer and Immunology Trials at Salzburg Cancer Research Institute, Salzburg, Austria.; Cancer Cluster Salzburg, Salzburg, Austria.
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2016 Apr 16; Vol. 9, pp. 39. Date of Electronic Publication: 2016 Apr 16.
Typ publikacji:
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Azacitidine/*therapeutic use
Leukemia, Myeloid/*drug therapy
Myelodysplastic Syndromes/*drug therapy
Registries/*statistics & numerical data
Acute Disease ; Adult ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic/therapeutic use ; Austria ; Female ; France ; Humans ; Kaplan-Meier Estimate ; Leukemia, Myeloid/classification ; Leukemia, Myeloid/diagnosis ; Male ; Middle Aged ; Myelodysplastic Syndromes/classification ; Myelodysplastic Syndromes/diagnosis ; Outcome Assessment, Health Care/methods ; Outcome Assessment, Health Care/statistics & numerical data ; Prognosis ; Proportional Hazards Models ; United Kingdom ; United States ; World Health Organization
Czasopismo naukowe
    Wyświetlanie 1-19 z 19

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies